Regional Cancer Care Associates Cancer and Hematologic Disease — Cherry Hill, New Jersey

Regional Cancer Care Associates Cancer and Hematologic Disease is a clinical research site located in Cherry Hill, New Jersey, United States 08003.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Regional Cancer Care Associates Cancer and Hematologic Disease has participated in 1 clinical trials.

Therapeutic areas: Advanced Breast Cancer.

Sponsors: Novartis Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Cherry Hill

Browse all research sites in New Jersey · View every site in Cherry Hill

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Regional Cancer Care Associates Cancer and Hematologic Disease?

Regional Cancer Care Associates Cancer and Hematologic Disease has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Regional Cancer Care Associates Cancer and Hematologic Disease conducted?

Regional Cancer Care Associates Cancer and Hematologic Disease has 1 clinical trials on record. Their work covers Advanced Breast Cancer.

Is Regional Cancer Care Associates Cancer and Hematologic Disease accredited by Crixeo Clinical Trials?

Regional Cancer Care Associates Cancer and Hematologic Disease has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Regional Cancer Care Associates Cancer and Hematologic Disease?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.